MetaVia (MTVA) announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH.

The "Dengue Fever - Global Clinical Trials Review, 2024" has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of the Dengue Fever Clinical trials scenario ...

Each of the two parts of the Phase 2a trial of DA-1241 were designed ... For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06054815. About DA-1241 DA-1241 ...

Bioxodes enrolls patients in phase 2a clinical trial of BIOX-101 in intracerebral hemorrhagic stroke: Gosselies, Belgium Saturday, December 21, 2024, 15:00 Hrs [IST] Bioxodes SA, ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

(RTTNews) - MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

MIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in ...

Topline data from both the Phase 2 ACeD-it and Phase 2a SynCeD clinical trials are expected in the first half of 2025. KAN-101 is a novel immune tolerance therapy, which encompasses an established ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

Each of the two parts of the Phase 2a trial of DA-1241 were designed to be 16-week ... For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06054815. About DA-1241 ...